Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eylea, Regeneron and Amgen
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.
Regeneron’s Eylea biosimilar fight heats up
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating for REGN stock.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
The lawsuit was related to a biosimilar of its lead drug
Eylea
(aflibercept 2 mg). Regeneron’s shares have rallied 24.3% year to date against the industry’s decline of 1.5%. Image Source ...
2d
on MSN
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Bio…
Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...
6d
on MSN
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar (update)
Adds Wells Fargo analyst comment. Regeneron Pharmaceuticals (NASDAQ:REGN) quickly dropped 3.5% after a judge denied the ...
ENDPOINTS NEWS
5d
Federal judge rules against Regeneron's attempt to halt Amgen from launching Eylea biosimilar
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...
STAT
5d
Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
1d
Regeneron: Long-Term Defensive Investment
Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...
6d
Buy Rating Affirmed for Regeneron Despite Eylea Legal Challenges: Growth and Diversification Fuels Optimism
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Medscape
9d
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...
2d
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Regeneron
Amgen
Feedback